The SARS-CoV-2 virus is regulated by the binding of its glycoprotein to ACE2, and it is proposed that an increase in the expression of ACE2 in patients with AD favors the binding of SARS-CoV-2 to the respiratory epithelium, pulmonary parenchyma, cardiomyocytes, and vascular endothelium [31,50]. Here, ACE2 is linked to Alzheimer disease.